| Literature DB >> 29480172 |
Wei Zhang1, Yi Guo2, Bo Li1, Qi Zhang3, Jian-Hui Liu4, Guo-Jun Gu2, Jin-Hong Wang5, Rui-Kang Bao6, Yu-Jie Chen7, Jian-Rong Xu1.
Abstract
Cerebral amyloid angiopathy (CAA) is present in up to 90% of patients with Alzheimer's disease (AD), and may interact with classical neuropathology to exacerbate cognitive decline. Since growth differentiation factor 11 (GDF11) can activate vascular remodeling, we tested its effects on cognitive function and neuroinflammatory changes of AD model mice. We intravenously administered GDF11 or vehicle daily to 12-month-old transgenic mice overexpressing the amyloid-β protein precursor (AβPP)/PS1). Cognitive function was monitored using the Morris water maze, and after conclusion of the treatment, we assessed the morphology and presence of inflammatory markers in the cerebral vasculature. Subchronic treatment of adult AβPP/PS1 mice with GDF11 rescued cognitive function and ameliorated cerebrovascular function. In particular, the de novo genesis of small blood vessels and the expression of vascular-related proteins were significantly higher than in the vehicle-treated AβPP/PS1 mice, whereas the expressions of the inflammatory markers Iba-1 and GFAP significantly decreased in proportion to the lower ratio of two forms of amyloid-β (Aβ40/42). Daily intravenous treatment with GDF11-injection can rejuvenate respects of cognition and cerebrovascular changes in AD mice.Entities:
Keywords: Alzheimer’s disease; cerebral amyloid angiopathy; cerebral blood flow; growth differentiation factor 11; neuroinflammation
Mesh:
Substances:
Year: 2018 PMID: 29480172 DOI: 10.3233/JAD-170474
Source DB: PubMed Journal: J Alzheimers Dis ISSN: 1387-2877 Impact factor: 4.472